| UHC Medicaid Medical & Drug | Diagnostic Dynamic Spinal Visualization and Vertebral Motion Analysis – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Factor Mimetics and Rebalancing Agents for Hemophilia – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | FcRn Blockers – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Gamifant® (Emapalumab-Lzsg) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Genetic Testing for Cardiac Disease – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Ilumya® (Tildrakizumab-Asmn) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Inhaled Nitric Oxide Therapy – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Injectable Dermal Fillers and Bulking Agents – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Itvisma® (Onasemnogene Abeparvovec-Brve) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |